Saigal, Christopher S.; Litwin, Mark S. - In: PharmacoEconomics 20 (2002) 13, pp. 869-878
The economic costs of early stage prostate cancer are significant, and will likely increase as the proportion of older men grows in the population of industrialised nations. In the US, total costs have been estimated to range from $US1.72 billion to $US4.75 billion annually (1990 costs). Costs...